Navigation Links
AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
Date:1/11/2013

Alachua, FL (PRWEB) January 11, 2013

AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today that Avance® Nerve Graft, a processed nerve allograft for surgical repair and reconstruction of peripheral nerve segmental defects, will be featured in multiple presentations at The American Society for Peripheral Nerves (ASPN) and The American Society for Reconstructive Microsurgery (ASRM) 2013 Annual Meetings, January 12-15 in Naples, Florida. In addition, AxoGen will be exhibiting its products at Booth 42 throughout the duration of the meetings.

“We are very excited about the increasing interest from the surgeon community,” said Jill Schiaparelli, Senior Vice President of Business Strategy and Marketing for AxoGen. “We are pleased to have several clinical experts in nerve repair presenting data on Avance® Nerve Graft.”

Avance® Nerve Graft is processed nerve allograft intended for the reconstruction of peripheral nerve discontinuities to support axon regeneration across the gap and provides surgeons a readily available nerve graft to repair peripheral nerves damaged by traumatic injury or removed during a surgical procedure.

Presentations on clinical experience with Avance® Nerve Graft at the ASPN and ASRM meetings include:

“Comparisons of Functional Recovery Outcomes with increasingly Rigorous Threshold Parameters from a Multicenter Registry Study of Processed Nerve Allografts,” by RANGER® Registry investigator Gregory Buncke, MD of The Buncke Clinic, January 12, 2013, 4:30-5:30 pm

“Quantitative Outcomes from a Multicenter Registry Study of Processed Nerve Allografts in Sensory and Mixed Repairs Presenting with Concomitant injuries,” by RANGER® Registry investigator Wesley Thayer, MD, PhD, Vanderbilt University, Torso and Trunk Session, January 14, 2013, 2:15-3:30 pm

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

The RANGER® Registry is sponsored by AxoGen with nominal funding provided to each center to support the data collection process. All data analysis is handled by an independent biostatistician and no surgeon is compensated for implanting Avance® Nerve Graft.
For more information, visit our website at http://www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10313599.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
2. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
3. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
4. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
5. University of Houston Graduate College of Social Work announces partnership with MD Anderson
6. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
7. AGA announces prestigious awards recognition recipients
8. TheBestHeartRateMonitorReviews.com Announces The Top 3 Heart Rate Monitors
9. Article Marketing Company Content Writing King Announces Training Of New Graphic Design Artist
10. Zane Benefits Announces Wellness HRAs: A New Way to Reward Healthy Employees
11. San Francisco’s Advanced Male Medical Center Announces Discount, Discusses Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... ODU, a worldwide leader in ... its advanced highly customizable contact technology solutions. , ODU Single Contact Technology portfolio ... ideal for a wide range of applications that require customization from industries like ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Facial plastic surgeon, ... holiday season by donating a portion of proceeds to two local organizations: North Chicago ... Animal Control & Friends is a team of authorized and trained volunteers who ...
(Date:12/7/2016)... , ... December 07, 2016 , ... "ProBrand Flip allows ... all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip ... to use drop zones. Editors can select from a variety of flip book animations. ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... JOLLA, Calif. , Dec. 6, 2016 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development ... new drug development candidates at its R&D day, ... The first candidate, RGLS5040, is an anti-miR targeting ... The second candidate, RGLS4326, is an anti-miR targeting ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology: